Trials / Terminated
TerminatedNCT05992922
A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants
A Phase 2, Single-Center, Randomized, Double- Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution 1% in Subjects Diagnosed With Dry Eye Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Iacta Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability and efficacy of IC265 compared to vehicle in participants with signs and symptoms dry eye disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IC265 Ophthalmic Solution 1% | 1 drop will be instilled in each eye twice a day |
| DRUG | Placebo Ophthalmic Solution (Vehicle) | 1 drop will be instilled in each eye twice a day |
Timeline
- Start date
- 2023-10-17
- Primary completion
- 2023-12-19
- Completion
- 2023-12-19
- First posted
- 2023-08-15
- Last updated
- 2025-04-25
- Results posted
- 2025-04-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05992922. Inclusion in this directory is not an endorsement.